7
/ 49
7
/ 49
16
/ 112
30
/ 210
0
7
/ 49
7
/ 49
16
/ 112
30
/ 210
0
The Positive and Negative Syndrome Scale (PANSS) is the most comprehensive and widely used clinician-rated instrument for assessing the symptom severity of schizophrenia and related psychotic disorders. Developed by Stanley Kay, Abraham Fiszbein, and Lewis Opler in 1987, the PANSS was designed to address limitations of earlier psychosis rating scales by providing balanced assessment of positive symptoms, negative symptoms, and general psychopathology within a single integrated instrument.
Schizophrenia is a chronic, debilitating mental disorder affecting approximately 1% of the global population (24 million people). It is characterized by a complex constellation of symptoms traditionally divided into positive symptoms (hallucinations, delusions, thought disorder) that reflect an excess or distortion of normal function, and negative symptoms (affective flattening, avolition, alogia, anhedonia) that reflect a diminution or loss of normal function. Understanding the balance between these symptom dimensions is crucial for treatment planning and prognosis.
The PANSS consists of 30 items organized into three subscales. The Positive Scale (P1-P7) assesses delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The Negative Scale (N1-N7) evaluates blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking. The General Psychopathology Scale (G1-G16) captures additional psychiatric symptoms including anxiety, guilt, depression, motor retardation, and active social avoidance.
Each item is rated on a 7-point scale (1 = absent to 7 = extreme), with detailed anchoring descriptions for each severity level. The minimum total score is 30 (all items rated 1) and the maximum is 210 (all items rated 7). Subscale scores range from 7-49 for Positive and Negative scales, and 16-112 for General Psychopathology. The Composite Index, calculated as the Positive minus Negative subscale score, indicates whether the clinical presentation is predominantly positive (positive values) or negative (negative values).
The PANSS has demonstrated excellent psychometric properties across numerous validation studies. Inter-rater reliability is high (ICC 0.83-0.92), internal consistency is good (Cronbach's alpha 0.73-0.83 for subscales), and test-retest reliability is adequate. The instrument shows strong convergent validity with other established psychosis rating scales and discriminant validity in distinguishing between clinical subtypes of schizophrenia.
In clinical trials, the PANSS total score is the standard primary efficacy endpoint for antipsychotic drug evaluation. The FDA and EMA accept PANSS as the primary outcome measure for registration trials. Treatment response is typically defined as a 30% or greater reduction in total PANSS score (after subtracting the minimum possible score of 30), while remission criteria require scores of 3 or less on eight core items maintained for at least 6 months.
This calculator provides scoring for the Positive and Negative subscales with individual item entry and accepts a pre-calculated General Psychopathology total, generating comprehensive PANSS scoring including the Composite Index for symptom profile characterization.
Administration of the full PANSS requires extensive clinical training and typically takes 40-50 minutes through a semi-structured interview. Standardized training programs (SCI-PANSS) ensure reliable administration across clinical settings and research sites, which is essential for the validity of multi-center clinical trials.
The PANSS rates 30 items on a 1-7 scale each: 7 Positive items (P1-P7, range 7-49), 7 Negative items (N1-N7, range 7-49), and 16 General Psychopathology items (G1-G16, range 16-112). Total PANSS = P + N + G (range 30-210). The Composite Index = Positive total minus Negative total: positive values suggest predominantly positive symptoms, negative values suggest predominantly negative presentation.
Total Score 30-58: Mildly ill or remission. 59-75: Moderately ill. 76-95: Markedly ill. 96+: Severely ill. Composite Index: Positive values indicate predominant positive symptoms; negative values indicate predominant negative symptoms. Treatment response: ≥30% reduction from baseline (adjusted for minimum score of 30). Remission: Scores ≤3 on P1, P2, P3, N1, N4, N6, G5, G9 for ≥6 months.
Inputs
Results
Total 72 (moderately ill). Composite +11 indicates predominantly positive symptom presentation.
Inputs
Results
Total 80 (markedly ill). Composite -20 indicates predominantly negative symptoms requiring targeted interventions.
The Positive and Negative Syndrome Scale is a 30-item clinician-rated instrument for measuring schizophrenia symptom severity. Developed by Kay, Fiszbein, and Opler in 1987, it assesses positive symptoms (7 items), negative symptoms (7 items), and general psychopathology (16 items). It is the gold standard outcome measure in schizophrenia clinical trials.
The PANSS uses a 1-7 scale where 1 represents 'Absent' rather than starting at 0. This means the minimum total score is 30 (not 0). When calculating percentage improvement, the baseline minimum of 30 must be subtracted: % improvement = (baseline - endpoint) / (baseline - 30) x 100.
The Composite Index equals the Positive subscale score minus the Negative subscale score. It ranges from -42 to +42. Positive values indicate a predominantly positive symptom profile (hallucinations, delusions dominant), while negative values indicate a predominantly negative profile (apathy, withdrawal dominant). This helps characterize the clinical phenotype.
Response is typically defined as a ≥30% reduction in total PANSS score adjusted for the minimum: [(Baseline - Endpoint) / (Baseline - 30)] x 100 ≥ 30%. Some studies use 20%, 40%, or 50% thresholds. Remission requires scores of ≤3 on 8 core items (P1, P2, P3, N1, N4, N6, G5, G9) maintained for ≥6 months.
Full PANSS administration typically requires 40-50 minutes using the Structured Clinical Interview for PANSS (SCI-PANSS). The interview includes rapport-building, assessment of current symptoms and history, and behavioral observation. Experienced raters may complete it more quickly, while complex presentations may require longer assessment.
While designed for schizophrenia, the PANSS has been used in research on schizoaffective disorder, delusional disorder, psychotic depression, and bipolar disorder with psychotic features. Its broader application is supported by the general psychopathology subscale, though interpretation should consider the original validation context.
Formal training in the SCI-PANSS is recommended, typically involving didactic instruction, video-based training, and calibration exercises. In clinical trials, raters must demonstrate inter-rater reliability (ICC ≥0.80) before independent scoring. Training programs are available from the PANSS Institute and other organizations.
The G items assess: G1 somatic concern, G2 anxiety, G3 guilt feelings, G4 tension, G5 mannerisms/posturing, G6 depression, G7 motor retardation, G8 uncooperativeness, G9 unusual thought content, G10 disorientation, G11 poor attention, G12 lack of judgment/insight, G13 disturbance of volition, G14 poor impulse control, G15 preoccupation, G16 active social avoidance.
The PANSS Negative Scale measures 7 domains: blunted affect, emotional withdrawal, poor rapport, passive social withdrawal, difficulty in abstract thinking, lack of spontaneity, and stereotyped thinking. However, factor analysis suggests primary negative symptoms (deficit symptoms) and secondary negative symptoms (due to medication or depression) may be distinguished through clinical context.
A change of approximately 15-20 points on the total PANSS corresponds to a 1-point change on the Clinical Global Impression scale. In clinical trials, the minimum clinically important difference is generally considered to be a 10-15 point change or approximately 15-20% reduction from baseline (adjusted for minimum score).
Roboculator Team
The Roboculator Team explains calculations, planning tools, and practical formulas in clear language for real-life situations.
How helpful was this calculator?
Be the first to rate!
CAGE Questionnaire (Alcohol)
Psychiatric Assessment Tools
Fagerstrom Test for Nicotine Dependence
Psychiatric Assessment Tools
Insomnia Severity Index (ISI)
Psychiatric Assessment Tools
MDQ (Mood Disorder Questionnaire)
Psychiatric Assessment Tools
Young Mania Rating Scale (YMRS)
Psychiatric Assessment Tools
AUDIT-C (Alcohol Use Disorders)
Psychiatric Assessment Tools
